The University of Chicago Header Logo

Connection

Richard A. Larson to Precursor Cell Lymphoblastic Leukemia-Lymphoma

This is a "connection" page, showing publications Richard A. Larson has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
  1. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Curr Hematol Malig Rep. 2023 12; 18(6):217-225.
    View in: PubMed
    Score: 0.659
  2. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700.
    View in: PubMed
    Score: 0.587
  3. Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 01; 59(1):3-13.
    View in: PubMed
    Score: 0.430
  4. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5.
    View in: PubMed
    Score: 0.334
  5. Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Curr Opin Oncol. 2009 Nov; 21(6):601-8.
    View in: PubMed
    Score: 0.255
  6. Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):11-6.
    View in: PubMed
    Score: 0.240
  7. Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant. 2008 Aug; 42 Suppl 1:S18-S24.
    View in: PubMed
    Score: 0.233
  8. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S13-20.
    View in: PubMed
    Score: 0.223
  9. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42.
    View in: PubMed
    Score: 0.212
  10. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15; 109(10):4164-7.
    View in: PubMed
    Score: 0.210
  11. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006 Apr; 43(2):126-33.
    View in: PubMed
    Score: 0.199
  12. Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec; 6(15):2711-8.
    View in: PubMed
    Score: 0.194
  13. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005; 131-6.
    View in: PubMed
    Score: 0.182
  14. Adult ALL: where are we and where are we going? Clin Adv Hematol Oncol. 2004 Jun; 2(6):342-4.
    View in: PubMed
    Score: 0.175
  15. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.174
  16. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.170
  17. The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 Suppl 1:S127-8.
    View in: PubMed
    Score: 0.170
  18. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.169
  19. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):284-9.
    View in: PubMed
    Score: 0.164
  20. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9.
    View in: PubMed
    Score: 0.161
  21. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80.
    View in: PubMed
    Score: 0.161
  22. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204.
    View in: PubMed
    Score: 0.159
  23. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol. 2002 Dec; 15(4):597-621.
    View in: PubMed
    Score: 0.158
  24. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.154
  25. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307.
    View in: PubMed
    Score: 0.140
  26. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
    View in: PubMed
    Score: 0.140
  27. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231.
    View in: PubMed
    Score: 0.139
  28. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.139
  29. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x.
    View in: PubMed
    Score: 0.137
  30. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
    View in: PubMed
    Score: 0.129
  31. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.
    View in: PubMed
    Score: 0.126
  32. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192.
    View in: PubMed
    Score: 0.126
  33. Dose-intensive therapy for adult acute lymphoblastic leukemia. Semin Oncol. 1999 Feb; 26(1):6-20.
    View in: PubMed
    Score: 0.121
  34. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.121
  35. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64.
    View in: PubMed
    Score: 0.117
  36. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):660-5.
    View in: PubMed
    Score: 0.115
  37. Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997 Feb; 24(1):70-82.
    View in: PubMed
    Score: 0.105
  38. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
    View in: PubMed
    Score: 0.104
  39. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.
    View in: PubMed
    Score: 0.099
  40. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
    View in: PubMed
    Score: 0.098
  41. Current management of acute lymphoblastic leukemia in adults. Oncology (Williston Park). 1995 May; 9(5):433-42; discussion 442-4, 449-50.
    View in: PubMed
    Score: 0.093
  42. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37.
    View in: PubMed
    Score: 0.093
  43. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
    View in: PubMed
    Score: 0.091
  44. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia. 2013 Jun; 27(6):1411-3.
    View in: PubMed
    Score: 0.078
  45. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.077
  46. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012 Jan; 18(1):16-7.
    View in: PubMed
    Score: 0.073
  47. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012 Jan; 18(1):18-36.e6.
    View in: PubMed
    Score: 0.072
  48. Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults. Curr Opin Oncol. 1991 Feb; 3(1):30-8.
    View in: PubMed
    Score: 0.069
  49. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View in: PubMed
    Score: 0.065
  50. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9.
    View in: PubMed
    Score: 0.062
  51. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.
    View in: PubMed
    Score: 0.058
  52. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19971-6.
    View in: PubMed
    Score: 0.056
  53. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 01; 110(7):2309-15.
    View in: PubMed
    Score: 0.054
  54. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006 Jan; 12(1):1-30.
    View in: PubMed
    Score: 0.049
  55. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res. 2005 Nov 15; 11(22):8089-96.
    View in: PubMed
    Score: 0.048
  56. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005 Nov; 11(11):823-61.
    View in: PubMed
    Score: 0.048
  57. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88.
    View in: PubMed
    Score: 0.043
  58. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999 Jun 01; 93(11):3931-9.
    View in: PubMed
    Score: 0.031
  59. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999 Jun 01; 93(11):3983-93.
    View in: PubMed
    Score: 0.031
  60. High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):391-6.
    View in: PubMed
    Score: 0.028
  61. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
    View in: PubMed
    Score: 0.026
  62. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996 May; 10(5):795-802.
    View in: PubMed
    Score: 0.025
  63. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):293-320.
    View in: PubMed
    Score: 0.025
  64. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995 Jan; 9(1):95-101.
    View in: PubMed
    Score: 0.023
  65. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.022
  66. Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer Res. 1994 Sep 15; 54(18):4999-5004.
    View in: PubMed
    Score: 0.022
  67. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 1992 Dec 15; 80(12):2983-90.
    View in: PubMed
    Score: 0.020
  68. Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia. Leukemia. 1992; 6 Suppl 2:171-4.
    View in: PubMed
    Score: 0.018
  69. Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation. Blood. 1991 Mar 01; 77(5):1087-91.
    View in: PubMed
    Score: 0.017
  70. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.017
  71. Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med. 1990 Jan 11; 322(2):77-82.
    View in: PubMed
    Score: 0.016
  72. Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91.
    View in: PubMed
    Score: 0.010
  73. t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes Cancer. 2002 Jun; 34(2):186-92.
    View in: PubMed
    Score: 0.010
  74. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993 Dec 15; 82(12):3705-11.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.